CU24292B1 - N-(6-((2r, 3s)- 3,4- dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio) pirimidin-4-il)-3- metilacetidina-1-sulfonamida como modulador del receptor de quimiocina - Google Patents
N-(6-((2r, 3s)- 3,4- dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio) pirimidin-4-il)-3- metilacetidina-1-sulfonamida como modulador del receptor de quimiocinaInfo
- Publication number
- CU24292B1 CU24292B1 CUP2014000004A CU20140004A CU24292B1 CU 24292 B1 CU24292 B1 CU 24292B1 CU P2014000004 A CUP2014000004 A CU P2014000004A CU 20140004 A CU20140004 A CU 20140004A CU 24292 B1 CU24292 B1 CU 24292B1
- Authority
- CU
- Cuba
- Prior art keywords
- methylacetidine
- fluorobencilti
- dihydroxibutan
- chemiocine
- iloxi
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
- C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/20—Free hydroxyl or mercaptan
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/78—Benzoic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/12—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Abstract
<p>Se proporciona un compuesto que es una sulfonamida pirimidina de fórmula (I), formas cristalinas del compuesto, intermediarios farmacéuticos utilizados en la fabricación del compuesto.</p> <p>ESPACIO PARA FORMULA I </p> <p>El compuesto es útil en el tratamiento de una enfermedad/ trastorno en donde la modulación de la actividad del receptor de quimiocina es beneficiosa.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161506737P | 2011-07-12 | 2011-07-12 | |
PCT/GB2012/051620 WO2013008002A1 (en) | 2011-07-12 | 2012-07-10 | N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20140004A7 CU20140004A7 (es) | 2014-05-27 |
CU24292B1 true CU24292B1 (es) | 2017-12-08 |
Family
ID=46513787
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CUP2014000004A CU24292B1 (es) | 2011-07-12 | 2012-07-10 | N-(6-((2r, 3s)- 3,4- dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio) pirimidin-4-il)-3- metilacetidina-1-sulfonamida como modulador del receptor de quimiocina |
CUP2016000083A CU20160083A7 (es) | 2011-07-12 | 2016-06-10 | Un proceso para preparar el compuesto (r)-1-((s)-2,2-dimetil-1,3-dioxolan-4-il)etanol y sus productos intermediarios |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CUP2016000083A CU20160083A7 (es) | 2011-07-12 | 2016-06-10 | Un proceso para preparar el compuesto (r)-1-((s)-2,2-dimetil-1,3-dioxolan-4-il)etanol y sus productos intermediarios |
Country Status (37)
Country | Link |
---|---|
US (3) | US8735413B2 (es) |
EP (2) | EP3255043B1 (es) |
JP (2) | JP6006308B2 (es) |
KR (1) | KR101946664B1 (es) |
CN (1) | CN103781781B (es) |
AR (2) | AR087168A1 (es) |
AU (2) | AU2012282316B2 (es) |
BR (1) | BR112014000636B1 (es) |
CA (1) | CA2841859C (es) |
CL (1) | CL2014000079A1 (es) |
CO (1) | CO6852072A2 (es) |
CR (1) | CR20140007A (es) |
CU (2) | CU24292B1 (es) |
CY (1) | CY1124329T1 (es) |
DK (1) | DK3255043T3 (es) |
DO (1) | DOP2013000308A (es) |
EA (1) | EA027821B1 (es) |
EC (1) | ECSP14013130A (es) |
ES (1) | ES2861927T3 (es) |
HK (1) | HK1245779A1 (es) |
HR (1) | HRP20210413T1 (es) |
HU (1) | HUE053703T2 (es) |
IL (1) | IL230398A (es) |
LT (1) | LT3255043T (es) |
MX (2) | MX353334B (es) |
MY (1) | MY180039A (es) |
NI (1) | NI201400002A (es) |
PE (2) | PE20181069A1 (es) |
PL (1) | PL3255043T3 (es) |
PT (1) | PT3255043T (es) |
RS (1) | RS61608B1 (es) |
SG (1) | SG10201605619XA (es) |
SI (1) | SI3255043T1 (es) |
TW (2) | TWI659026B (es) |
UY (1) | UY34191A (es) |
WO (1) | WO2013008002A1 (es) |
ZA (1) | ZA201401059B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012007748A1 (en) | 2010-07-13 | 2012-01-19 | Astrazeneca Ab | New crystalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3-dihydroxy-1- methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide |
RS61608B1 (sr) * | 2011-07-12 | 2021-04-29 | Astrazeneca Ab | N- (6 - ((2r, 3s) -3,4-dihidroksibutan-2-iloksi) -2- (4-fluorobenziltio) pirimidin-4-il) -3- metilazetidin-1-sulfonamid kao modulator receptora hemokina |
EP3141235A1 (en) * | 2012-12-06 | 2017-03-15 | IP Gesellschaft für Management mbH | N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3-methylazetidine-l -sulfonamide |
AU2017231832B2 (en) * | 2016-03-11 | 2021-11-11 | Ardea Biosciences, Inc. | CXCR-2 inhibitors for treating crystal arthropathy disorders |
BR112020004697A2 (pt) * | 2017-09-12 | 2020-10-27 | Ardea Biosciences, Inc. | inibidores de cxcr-2 para tratamento de distúrbios |
EP3983368B1 (en) | 2019-06-12 | 2023-08-02 | Nouryon Chemicals International B.V. | Process for the production of diacyl peroxides |
US20220306490A1 (en) * | 2019-06-12 | 2022-09-29 | Nouryon Chemicals International B.V. | Method for isolating carboxylic acid from an aqueous side stream |
EP3983370B1 (en) | 2019-06-12 | 2023-08-02 | Nouryon Chemicals International B.V. | Process for the production of diacyl peroxides |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3457278A (en) * | 1964-10-15 | 1969-07-22 | Geigy Chem Corp | Cyclopropyl-4-sulfanilamido-pyrimidines |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
EP0880508B1 (en) | 1996-02-13 | 2003-04-16 | AstraZeneca AB | Quinazoline derivatives as vegf inhibitors |
ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
FI981521A0 (fi) * | 1998-07-01 | 1998-07-01 | Orion Corp | Substituoidut beta-diketonit ja niiden käyttö |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
KR20030013433A (ko) | 2000-05-31 | 2003-02-14 | 아스트라제네카 아베 | 혈관 손상 활성을 가진 인돌 유도체 |
EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
AU6623301A (en) | 2000-07-07 | 2002-01-21 | Angiogene Pharm Ltd | Colchinol derivatives as vascular damaging agents |
GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
GB0419235D0 (en) * | 2004-08-28 | 2004-09-29 | Astrazeneca Ab | Compounds |
JP4795352B2 (ja) * | 2004-08-28 | 2011-10-19 | アストラゼネカ・アクチエボラーグ | ケモカイン受容体モジュレーターとしてのピリミジンスルホンアミド誘導体 |
WO2007083182A2 (en) * | 2006-01-19 | 2007-07-26 | Orchid Research Laboratories Limited | Novel heterocycles |
WO2008157273A1 (en) * | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Chemical compounds |
MX2011000402A (es) * | 2008-07-16 | 2011-03-15 | Astrazeneca Ab | Derivado de pirimidil sulfonamida y su uso para el tratamiento de enfermedades mediadas por quimiocinas. |
JP2011529027A (ja) | 2008-07-25 | 2011-12-01 | ビーエーエスエフ ソシエタス・ヨーロピア | 3−アミノメチル−1−シクロヘキシルアミン、及びその製造方法 |
WO2012007748A1 (en) * | 2010-07-13 | 2012-01-19 | Astrazeneca Ab | New crystalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3-dihydroxy-1- methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide |
RS61608B1 (sr) * | 2011-07-12 | 2021-04-29 | Astrazeneca Ab | N- (6 - ((2r, 3s) -3,4-dihidroksibutan-2-iloksi) -2- (4-fluorobenziltio) pirimidin-4-il) -3- metilazetidin-1-sulfonamid kao modulator receptora hemokina |
-
2012
- 2012-07-10 RS RS20210370A patent/RS61608B1/sr unknown
- 2012-07-10 PL PL16202983T patent/PL3255043T3/pl unknown
- 2012-07-10 DK DK16202983.9T patent/DK3255043T3/da active
- 2012-07-10 PT PT162029839T patent/PT3255043T/pt unknown
- 2012-07-10 KR KR1020147000487A patent/KR101946664B1/ko active IP Right Grant
- 2012-07-10 ES ES16202983T patent/ES2861927T3/es active Active
- 2012-07-10 AU AU2012282316A patent/AU2012282316B2/en not_active Ceased
- 2012-07-10 SG SG10201605619XA patent/SG10201605619XA/en unknown
- 2012-07-10 EP EP16202983.9A patent/EP3255043B1/en active Active
- 2012-07-10 JP JP2014519625A patent/JP6006308B2/ja not_active Expired - Fee Related
- 2012-07-10 CU CUP2014000004A patent/CU24292B1/es unknown
- 2012-07-10 BR BR112014000636-9A patent/BR112014000636B1/pt not_active IP Right Cessation
- 2012-07-10 LT LTEP16202983.9T patent/LT3255043T/lt unknown
- 2012-07-10 CN CN201280044385.0A patent/CN103781781B/zh active Active
- 2012-07-10 PE PE2018000520A patent/PE20181069A1/es unknown
- 2012-07-10 SI SI201231899T patent/SI3255043T1/sl unknown
- 2012-07-10 WO PCT/GB2012/051620 patent/WO2013008002A1/en active Application Filing
- 2012-07-10 MX MX2016000277A patent/MX353334B/es unknown
- 2012-07-10 HU HUE16202983A patent/HUE053703T2/hu unknown
- 2012-07-10 MY MYPI2014700061A patent/MY180039A/en unknown
- 2012-07-10 EA EA201490077A patent/EA027821B1/ru not_active IP Right Cessation
- 2012-07-10 MX MX2013015085A patent/MX342874B/es active IP Right Grant
- 2012-07-10 PE PE2014000009A patent/PE20141944A1/es active IP Right Grant
- 2012-07-10 EP EP12735323.3A patent/EP2731945A1/en not_active Withdrawn
- 2012-07-10 CA CA2841859A patent/CA2841859C/en active Active
- 2012-07-11 TW TW106135796A patent/TWI659026B/zh not_active IP Right Cessation
- 2012-07-11 UY UY0001034191A patent/UY34191A/es not_active Application Discontinuation
- 2012-07-11 US US13/546,444 patent/US8735413B2/en active Active
- 2012-07-11 TW TW101124908A patent/TWI633098B/zh not_active IP Right Cessation
- 2012-07-12 AR ARP120102531A patent/AR087168A1/es not_active Application Discontinuation
-
2013
- 2013-12-17 DO DO2013000308A patent/DOP2013000308A/es unknown
-
2014
- 2014-01-09 NI NI201400002A patent/NI201400002A/es unknown
- 2014-01-09 CR CR20140007A patent/CR20140007A/es unknown
- 2014-01-09 IL IL230398A patent/IL230398A/en active IP Right Grant
- 2014-01-10 EC ECSP14013130 patent/ECSP14013130A/es unknown
- 2014-01-10 CO CO14004182A patent/CO6852072A2/es active IP Right Grant
- 2014-01-10 CL CL2014000079A patent/CL2014000079A1/es unknown
- 2014-02-11 ZA ZA2014/01059A patent/ZA201401059B/en unknown
- 2014-04-15 US US14/253,288 patent/US9221782B2/en not_active Expired - Fee Related
- 2014-11-03 HK HK18105226.5A patent/HK1245779A1/zh unknown
-
2015
- 2015-12-28 US US14/980,754 patent/US9975881B2/en active Active
-
2016
- 2016-06-10 CU CUP2016000083A patent/CU20160083A7/es unknown
- 2016-07-01 JP JP2016131785A patent/JP6261666B2/ja active Active
- 2016-10-12 AU AU2016244246A patent/AU2016244246B2/en not_active Ceased
-
2021
- 2021-03-12 HR HRP20210413TT patent/HRP20210413T1/hr unknown
- 2021-04-07 CY CY20211100296T patent/CY1124329T1/el unknown
-
2022
- 2022-01-21 AR ARP220100128A patent/AR124688A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU24292B1 (es) | N-(6-((2r, 3s)- 3,4- dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio) pirimidin-4-il)-3- metilacetidina-1-sulfonamida como modulador del receptor de quimiocina | |
CL2021000566A1 (es) | Procesos para fabricar ácido 2-((3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-((s)-1-(isopropilsulfonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético, intermediarios y procesos para fabricar los intermediarios, formas cristalinas del compuesto y los intermediarios. (divisional de la solicitud no. 2015003589) | |
CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
CR20150370A (es) | Compuestos antivirales | |
CL2014001855A1 (es) | Compuestos derivados de imidazopirrolidinona o sus sales, formas cristalinas; composicion farmaceutica que los comprende; y su uso para el tratamiento de un trastorno o enfermedad mediada por la actividad de mdm2 y/o mdm4 tales como enfermedades proliferativas, especialmente cancer. | |
PE20160874A1 (es) | Compuestos quimicos | |
DOP2012000105A (es) | Compuestos de espiropiperidina y uso farmaceutico del mismo para tratar la diabetes | |
GT201500042A (es) | Producción de dienos volátiles por deshidratación enzimática de alquenoles ligeros | |
CU20110207A7 (es) | Aril piridinas como inhibidoras de sintasa de aldosterona | |
ECSP13012770A (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina | |
ECSP14013251A (es) | Derivados de 5-flúor-4-imino-3-(sustituido)-3,4-dihidropirimidin-2(1h)ona | |
GT201500243A (es) | Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina | |
CL2012002082A1 (es) | Proceso para la preparacion de lacosamida, por hidroximetilación; compuestos intermediarios. | |
CO7380758A2 (es) | Derivados de la 2-(morfolin-4-il)-3-(1-amino-3-trifluorometil-piridin-4-il)-5-(oxazol-3-il-2-ona)-pirimidina, activos como inhibidores pi3k mtor, composiciones farmacéuticas del mismo, y sus métodos de fabricación | |
AR083755A1 (es) | Formas solidas del acido (s)-2-amino-3-(4-(-2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pirimidin-4-il)fenil)propanoico | |
DOP2014000092A (es) | N-(3-{[(3-{[2-cloro-5-(metoxi) fenil] amino} quinoxalin-2-il) amino] sulfonil} fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas | |
CU24289B1 (es) | Nuevo procedimiento para la síntesis de la agomelatina | |
RU2012138692A (ru) | 1-(4-этилфенил)-2-[3-(4-этилфенил)-2-(1н)-хиноксалинилиден]-1-этанон, обладающий анальгетической активностью | |
RU2011131475A (ru) | 2-гидрокси-4-метилфенил-4-оксо-2-бутеноат тиазониламмония, обладающий гипогликемической и ноотропной активностью | |
UY32088A (es) | Compuesto heterociclico | |
RU2011131477A (ru) | Аллидамид n-ацетилизатиновой кислоты, проявляющий противовоспалительную и анальгетическую активности | |
CU24291B1 (es) | Nuevo procedimiento de síntesis de la agomelatina |